offers clues to common cold cure
U.Va. researcher has brought humankind closer to one of its most
sought-after goals a cure for the common cold.
Frederick Hayden, professor of internal
medicine and pathology, has been experimenting with pleconaril,
a novel antiviral compound being developed for the treatment of
viral respiratory infection, known as the common cold.
National Institutes of Health estimates that Americans suffer
1 billion colds annually. Currently, there are no antiviral treatments
available which target the most common underlying cause of the
cold, picornaviruses, one of the largest and most important groups
of human pathogens.
presented some of his data recently at the 41st annual Interscience
Conference on Antimicrobial Agents and Chemotherapy, including
results from two randomized, double-blind, placebo-controlled
studies of 2,096 adults with cold symptoms.
treated with pleconaril saw an improvement in their symptoms within
a day of starting treatment, and symptoms remained milder than
those of the control group.